Completed PHASE3 INTERVENTIONAL NCT00004112

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoma

Interventions CHOP regimen cyclophosphamide doxorubicin hydrochloride prednisone rituximab vincristine sulfate

Updated 7 times since 2017 Last updated: Sep 20, 2024 Started: Sep 1, 1999 Primary completion: Dec 1, 2000 Completion: Mar 1, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004112, this PHASE3 trial focuses on Lymphoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Oct 2024 — Present [monthly]

Completed PHASE3
Sep 2024 — Oct 2024 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jan 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of Nebraska

Data source: University of Nebraska

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States
• Omaha, United States